Literature DB >> 1256005

Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency.

H L Fehm, K H Voigt, R Lang, K E Beinert, S Raptis, E F Pfeiffer.   

Abstract

Somatostatin (250 mug as a bolus i.v. and 250 mug as a 1-hr infusion) was administered to 5 patients with adrenal insufficiency of different origin. In each patient a sustained, progressive fall in plasma ACTH was observed during the infusion period. The mean maximal reduction in plasma ACTH was 43.8 +/- 5.9%. After cessation of the somatostatin infusion there was a rise of plasma ACTH to starting levels within 1/2 hour. These findings suggest that somatostatin is a potent inhibitor of ACTH secretion, however, only in a condition in which glucocorticoids are lacking.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1256005     DOI: 10.1007/BF01468882

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  Inhibition by somatostatin of ACTH secretion in Nelson's syndrome.

Authors:  J B Tyrrell; M Lorenzi; J E Gerich; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1975-06       Impact factor: 5.958

2.  Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels.

Authors:  S S Yen; T M Siler; G W DeVane
Journal:  N Engl J Med       Date:  1974-04-25       Impact factor: 91.245

3.  Spontaneous and stimulated secretion of QUSO-extractable immunoassayable ACTH in man.

Authors:  K H Voigt; H L Fehm; R Reck; E F Pfeiffer
Journal:  Klin Wochenschr       Date:  1974-06-01

4.  Effect of somatostatin on plasma glucose and insulin responses to glucagon and tolbutamide in man.

Authors:  J E Gerich; M Lorenzi; V Schneider; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1974-12       Impact factor: 5.958

5.  Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

Authors:  C H Mortimer; W M Tunbridge; D Carr; L Yeomans; T Lind; D H Coy; S R Bloom; A Kastin; C N Mallinson; G M Besser; A V Schally; R Hall
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

6.  Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly.

Authors:  R Hall; G M Besser; A V Schally; D H Coy; D Evered; D J Goldie; A J Kastin; A S McNeilly; C H Mortimer; C Phenekos; W M Tunbridge; D Weightman
Journal:  Lancet       Date:  1973-09-15       Impact factor: 79.321

7.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

8.  Effects of somatostatin on the secretion of thyrotropin and prolactin.

Authors:  W Vale; C Rivier; P Brazeau; R Guillemin
Journal:  Endocrinology       Date:  1974-10       Impact factor: 4.736

9.  Effects of somatostatin on gastric secretion and gastrin release in man.

Authors:  S Raptis; H C Dollinger; L von Berger; W Schlegel; K E Schröder; E F Pfeiffer
Journal:  Digestion       Date:  1975       Impact factor: 3.216

10.  Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone.

Authors:  R Burgus; N Ling; M Butcher; R Guillemin
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

View more
  15 in total

1.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

2.  Constitutive somatostatin receptor activity determines tonic pituitary cell response.

Authors:  Anat Ben-Shlomo; Cuiqi Zhou; Oxana Pichurin; Vera Chesnokova; Ning-Ai Liu; Michael D Culler; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2009-01-08

Review 3.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 4.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

5.  Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotropin secretion in mouse pituitary tumor cells.

Authors:  S Heisler; T D Reisine; V Y Hook; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

Review 6.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

7.  Long-term treatment of Nelson's syndrome by octreotide: a case report.

Authors:  L Petrini; M Gasperi; R Pilosu; A Marcello; E Martino
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

Review 8.  Use of octreotide acetate for control of symptoms in patients with islet cell tumors.

Authors:  P N Maton
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

9.  Somatostatinoma syndrome. Clinical, morphological and metabolic features and therapeutic aspects.

Authors:  V Schusdziarra; D Grube; H Seifert; J Galle; H Etzrodt; W Beischer; O Haferkamp; E F Pfeiffer
Journal:  Klin Wochenschr       Date:  1983-07-15

10.  Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome.

Authors:  P Ruszniewski; F Girard; R Benamouzig; M Mignon; S Bonfils
Journal:  Gut       Date:  1988-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.